What You Should Know:
- Avenda Health's AI mapping tool for prostate cancer, Unfold AI™, has received significant recognition by obtaining a new Category III CPT code in the 2024 Current Procedural Terminology (CPT) code set, signifying its status as a cutting-edge medical technology.
- The new Category III CPT code, X237T, outlines the tool's capabilities, describing it as a non-invasive prostate cancer estimation map that is derived from an augmented analysis of image-guided fusion
Read More
Cancer Detection
C2i Genomics, Riken Genesis Expands AI-Powered Whole-Genome MRD Cancer Detection Across Japan
What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of personalized medicine based on contract analysis of next-generation sequencing and exomes. The two companies have entered a collaboration agreement to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research.
- Under this agreement, RG will work with C2i Genomics to commercialize
Read More
Liver Cancer Awareness – Here’s What You Need to Know in 2023
By the end of 2022, nearly 42,00 new cases of primary liver cancer will be diagnosed in the United States. In fact, liver cancer incidence rates have more than tripled since 1980, marking an increased need for better detection and diagnosis.
We might not talk about liver cancer as much as we do breast or lung cancer, but it’s a real threat to millions of Americans – and we need to continue spreading awareness.
Early detection is especially critical in treating liver cancer.
Read More
C2i Genomics & AstraZeneca Partner to Advance Cancer Therapy
What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a strategic collaboration with AstraZeneca, a global life sciences and pharmaceutical leader.
- The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers.
- Expanding on a completion of AstraZeneca’s accelerator BeyondBio SCALE program for start-ups and successful technology validation, C2i Genomics and AstraZeneca
Read More
New Liquid Biopsy Detects Breast Cancer at Its Earliest Stages
What You Should Know:
- Exai Bio and researchers at UCSF released data demonstrating that Exai’s novel, RNA-based liquid biopsy platform accurately detected breast cancer at the earliest stages and smallest tumor sizes.
- Earlier detection of breast cancer is crucial for optimal patient outcomes but cannot always be achieved based on symptoms or mammography.
Non-Invasive Blood-Based Platform Delivers Promising Data on Detecting Breast Cancer At It’s Earliest Stages
Exai Bio is a
Read More
HLTH22 Day 3 News Summary
DispatchHealth Raises $330M for Hospital-at-Home Care
DispatchHealth, a provider of in-home medical care raises $330M led by Optum Ventures with support from current investors such as Humana (NYSE: HUM), Oak HC/FT, Echo Health Ventures and Questa Capital. New investors included Adams Street Partners, the Olayan Group, Silicon Valley Bank, Pegasus Tech Ventures and Blue Shield of California. Patients and their care partners can request DispatchHealth medical care via phone, mobile app, or
Read More
Haystack Oncology Launches with $56M for Post-Op Cancer Detection Tech
What You Should Know:
- Haystack Oncology ("Haystack"), an oncology company that applies the next generation of circulating tumor DNA (ctDNA) detection technology raises $56M in Series A financing led by Catalio Capital Management ("Catalio"), which co-founded Haystack through its private equity and structured equity investment vehicles. Additional investors include Bruker, Exact Ventures, the venture arm of Exact Sciences and Alexandria Venture
Read More
Naveris Raises $51M for Early Detection of Viral-Driven Cancers
What You Should Know:
- Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers, recently announced a $33.4M expansion of its Series A financing, bringing the total investment in Naveris to $51M.
- The financing was led by Gurnet Point Capital, joined by TechU Ventures and BrightEdge, the impact and venture capital arm of the American Cancer Society.
Using DNA Fragmentomics Technology to Detect
Read More
Freenome Launches Multi-Cancer Detection Study Pairing Multiomics with Real-World Data
What You Should Know:
- Freenome, a privately held biotech company, today announced the launch of the Sanderson Study, the company’s latest study of its multiomics platform, in combination with real-world data to detect multiple cancers.
- The study will encompass both traditional and real-world data to generate evidence of clinical validation for certain high- and elevated-risk populations while also refining the platform’s cancer classification and risk prediction models. In addition,
Read More
Cerner Collaboration to Increase Access to Cancer Clinical Trials
What You Should Know:
- Cerner, Elligo Health Research® and Freenome are collaborating to enable a clinical trial through the Learning Health Network to help advance early cancer detection.
- Together they will be using the research-activated network of health systems, real-world data (RWD) and multiomics technology, developed by Freenome, with the goal to help accelerate early cancer detection.
Importance of Early Cancer Detection
Early
Read More
